Sera Prognostics Inc

NASDAQ SERA

Data sourced from

and

Download Data

Sera Prognostics Inc EBITDA Per Share 2 year CAGR for the year ending December 31, 2023: 5.44%

Sera Prognostics Inc EBITDA Per Share 2 year CAGR is 5.44% for the year ending December 31, 2023, a -90.92% change year over year. EBITDA per share represents the Earnings Before Interest, Taxes, Depreciation, and Amortization allocated to each outstanding share of common stock. It provides insight into the per-share value of EBITDA and is commonly used in valuation analysis. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Sera Prognostics Inc EBITDA Per Share for the year ending December 31, 2022 was -1.43, a -28.08% change year over year.
Sera Prognostics Inc EBITDA Per Share for the year ending December 31, 2021 was -1.11, a -99.72% change year over year.
Sera Prognostics Inc EBITDA Per Share for the year ending December 31, 2020 was -0.56, a 29.52% change year over year.
Sera Prognostics Inc EBITDA Per Share for the year ending December 31, 2019 was -0.79.

NASDAQ: SERA

Sera Prognostics Inc

CEO	Dr. Gregory C. Critchfield M.D., M.S.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees	55
Sector	Healthcare
Industry	Diagnostics & research

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends